Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irsogladine + lafutidine
- Development stage
- Phase 1
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRI-1501 is a combination therapy of irsogladine and lafutidine, developed for the treatment of gastrointestinal disorders such as gastric ulcer. The specific mechanism of action for the combination is not detailed in available sources, but individually, lafutidine is a histamine H2 receptor antagonist and irsogladine enhances mucosal defense mechanisms. The developer and sponsor is Boryung Pharmaceutical Co., Ltd.[2][4]
- Other names
- irsogladine/lafutidine combination therapyBRI 1501[2]
02
Targets
PDE (Phosphodiesterase family)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on irsogladine + lafutidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irsogladine + lafutidine.